Statement of Changes in Beneficial Ownership (4)
April 03 2020 - 9:03AM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Ricardo Alonso |
2. Issuer Name and Ticker or Trading Symbol
Ra Pharmaceuticals, Inc.
[
RARX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks |
|
(Last)
(First)
(Middle)
C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/2/2020 |
|
(Street)
CAMBRIDGE, MA 02140
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 4/2/2020 | | D | | 2973 (1) | D | $48.00 (2) | 0 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | $0.84 | 4/2/2020 | | D | | | 2857 (2) | (3) | 6/14/2022 | Common Stock | 2857 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $2.87 | 4/2/2020 | | D | | | 14285 (2) | (3) | 12/11/2024 | Common Stock | 14285 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $2.87 | 4/2/2020 | | D | | | 30000 (2) | (3) | 12/10/2025 | Common Stock | 30000 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $5.60 | 4/2/2020 | | D | | | 31428 (2) | (3) | 8/16/2026 | Common Stock | 31428 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $16.64 | 4/2/2020 | | D | | | 60000 (2) | (3) | 2/1/2027 | Common Stock | 60000 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $7.33 | 4/2/2020 | | D | | | 26250 (2) | (3) | 2/1/2028 | Common Stock | 26250 | $0 (3) | 0 | D | |
| Stock Option (Right to Buy) | $21.00 | 4/2/2020 | | D | | | 107000 (2) | (3) | 2/1/2029 | Common Stock | 107000 | $0 (3) | 0 | D | |
| Restricted Stock Units | (4) | 4/2/2020 | | D | | | 4375 (2) | (4) | (4) | Common Stock | 4375 | $0 (4) | 0 | D | |
| Explanation of Responses: |
| (1) | Includes 2,973 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. |
| (2) | Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. |
| (3) | Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| (4) | Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. |
Remarks:
The Reporting Person is Chief Technology and Innovation Officer and Head of Research. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Ricardo Alonso
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140 |
|
| See Remarks |
|
Signatures
|
| /s/ David C. Lubner, Attorney-in Fact for Alonso Ricardo | | 4/3/2020 |
| **Signature of Reporting Person | Date |
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2023 to Apr 2024
